Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

Study Overview
=================
Brief Summary
-----------------
To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning).

Detailed Description
-----------------
The purposes of this study are: To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning) To improve the success rate of escitalopram treatment response for depressed patients

Official Title
-----------------
Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

Conditions
-----------------
Depression, Continuous Antidepressant Abuse, Adverse Reaction to Drug

Intervention / Treatment
-----------------
* Drug: Escitalopram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians Exclusion Criteria: received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Antidepressant treated group<br>Antidepressant treated group: depressed patients treated with Escitalopram | Drug: Escitalopram<br>* Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose<br>* Other names: Escitalopram : Lexapro;|
| No Intervention: other antidepressant treated group<br>other Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| biological value at 0 week and 8 weeks |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Genomic devices, Prediction of Escitalopram Response, Depressed Patients